11:18 AM
 | 
Dec 14, 2018
 |  BC Week In Review  |  Financial News  |  Completed Offerings

Versant launches Black Diamond to mine allosteric mutant oncogenes

Black Diamond Therapeutics Inc. (New York City, N.Y.) emerged from stealth on Dec. 11 with $20 million in a tranched series A round from Versant Ventures and a platform to find and drug allosteric mutant oncogenes (see "Black Diamond: Mapping Allostery").

It is the first company to launch from Versant's Ridgeline incubator...

Read the full 244 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >